ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Introduction Interleukin 2 inducible T cell kinase (ITK) is a TEC family tyrosine kinase expressed in T cells with an important role both in T cell receptor (TCR) signaling and T helper cell differentiation. Resting lymphocyte kinase (RLK), a closely related kinase, is redundant to ITK and is involved in the differentiation of naïve T cells into Th1 T cells. ITK-/- mice exhibit defects in Th2 differentiation while retaining the ability to differentiate into Th1 cells that secrete IFNγ; whereas, double ITK/RLK knockout mice exhibit profound defects in T cell function. Th1 cells are needed for various cytotoxic T cell functions such as destruction of tumor cells. CPI-818 is a covalent inhibitor of ITK (K_D 2.5nM) with > 100 fold selectivity over RLK and other TEC family kinases. CPI-818 is being evaluated in an ongoing phase 1 trial in patients (pts) with refractory T cell lymphomas (TCL). We now report that selective ITK blockade with CPI-818 induces Th1 skewing of normal T cells and demonstrates anti-tumor activity.

Methods Normal human peripheral blood mononuclear cells (PBMC) were stimulated in vitro for 6 days with anti-CD3/CD28 in the presence of CPI-818. Th1 cells were measured by flow cytometry based on ratio of IFNγ:IL4 staining cells. Sezary cells were similarly stimulated in the presence of CPI-818. Peripheral blood and tumor samples were stained with antibodies to CD3, 4, 8, 183, 196, 197 and 45RA to enumerate Th1 and other T cell subsets using multicolor flow cytometry. Successive cohorts of TCL pts were treated in a phase 1 trial until disease progression with continuous oral dosing of CPI-818 100mg, 200mg, 400mg or 600mg given BID.

Results T cell receptor stimulated PBMC from 12 healthy donors incubated in vitro with CPI-818 demonstrated Th1 skewing at concentrations of 0.1 to < 10uM (Figure 1). Maximal skewing was seen at 1uM; cell viability was unaffected but, proliferation was inhibited at 10uM. Similar studies using Th2 Sezary cells showed inhibition of proliferation with CPI-818 (0.5-2.5uM). Thirty-three pts with TCL with a median age of 62 yrs and median of 4 prior therapies were enrolled. Histologies included: PTCL-NOS (17), AITL (4), and CTCL (12). The most common (≥ 10%) AEs were nausea, chills, vomiting, fatigue, pyrexia, decreased appetite, pruritus, and rash. Treatment-related Grade 3+ AEs were: anemia (1), lymphocytosis (1), WBC decreased (1) and neutropenia (1). The swimmer plot (Figure 2) shows a dose-dependent relationship with an optimum dose of 200mg (N=10) producing 1 CR 25 mo; 1 PR 2+ mo; 1 nodal CR 16 mo (CTCL); 2 SD; 1 PD; 4 not yet evaluated; 6 pts remain on treatment. Pharmacokinetic and target occupancy studies for the 200mg dose showed mean plasma Cmax of 2.3uM (SD 1.9uM) and ITK target occupancy of >75%. Analysis of blood in 4 of 4 pts treated in this cohort showed increases in Th1 cells (CD3+/CD4+/CD8-/CD183+/CD196-) compared to baseline and increases in terminally differentiated T effector memory cells (TEMRA CD3+/CD4-/CD8+/CD197-/CD45RA+). Tumor biopsy from 1 patient taken during response demonstrated an increase in Th1 (0 to 40%) and TEMRA CD8+ T cells (2.83% to 18.6%). CPI-818 reduced blood eosinophils (Eos) in 3 of 3 pts in this cohort with elevated Eos count, consistent with inhibition of Th2 function.

Conclusions This study demonstrates that selective inhibition of ITK, while sparing RLK, induces Th1 skewing. As expected, the effects on T cell differentiation and proliferation are dose dependent: lower doses induce Th1 skewing and higher concentrations in vitro and in vivo lead to inhibition of TCR signaling and proliferation. Tumor responses were observed in several patients receiving 200mg BID, which achieves drug plasma levels consistent with Th1 skewing observed in vitro. The increases in Th1 cells and TEMRA CD8+ cells suggest that anti-tumor activity is due to induction of a host anti-tumor response. This raises the possibility that immunomodulation with ITK blockade could be used for immunotherapy of other cancers.

Yoon:SAMYANG Biopharm: Honoraria, Research Funding; Boryung pharmaceutical: Honoraria, Research Funding; Beigene: Research Funding; Sanofi: Research Funding; Celltrion: Honoraria, Research Funding; Janssen Pharmaceuticals: Honoraria, Research Funding; Kirin Pharm: Honoraria, Research Funding; Roche: Honoraria; Amgen: Honoraria; BMS: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Pharos iBio: Consultancy; Ab clone: Consultancy; GI cell: Consultancy; GSK: Honoraria; Celgene: Honoraria; GC Cell: Consultancy; AbbVie: Research Funding. Reneau:Seattle Genetics: Research Funding; Bristol Myers Squibb: Research Funding; ADC Therapeutics: Research Funding; Merck: Research Funding; Corvus Pharmaceuticals, Inc.: Research Funding; Incyte: Research Funding; Kyowa Kirin: Membership on an entity's Board of Directors or advisory committees. Kim:Corvus: Membership on an entity's Board of Directors or advisory committees, Research Funding; Galderma: Honoraria, Research Funding; Trillium: Research Funding; Mundipharma: Honoraria; Eisai: Research Funding; Soligenix: Research Funding; Portola/Alexion Pharma: Research Funding; CRISPR Therapeutics: Research Funding; Secura Bio: Honoraria; Elorac: Research Funding; Kyowa Kirin: Honoraria, Research Funding; INNATE PHARMA: Membership on an entity's Board of Directors or advisory committees, Research Funding; Regeneron: Honoraria; Sanofi: Honoraria. Khodadoust:Myeloid Therapeutics: Membership on an entity's Board of Directors or advisory committees; Nutcracker Therapeutics: Research Funding; CRISPR Therapeutics: Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees. Feldman:MorphoSys: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kymera: Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Juno: Research Funding; Janssen Biotech, Inc.: Speakers Bureau; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Corvus Pharmaceuticals, Inc.: Research Funding; Celgene Corporation: Speakers Bureau; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Astrazeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pharmacyclics LLC: Speakers Bureau; Portola: Research Funding; Poteligeo: Speakers Bureau; SecuraBIO: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics, Inc.: Research Funding, Speakers Bureau; Takeda: Speakers Bureau; Tessa: Research Funding. Brammer:DrenBio: Consultancy; Kymera Therapeutics: Consultancy; Seattle Genetics: Speakers Bureau; Bristol-Myers Squibb: Research Funding. Hsu:Corvus Pharmaceuticals, Inc.: Current Employment. Yuan:Corvus Pharmaceuticals, Inc.: Current Employment. Verner:Corvus Pharmaceuticals, Inc.: Consultancy, Current equity holder in publicly-traded company. Mahabhashyam:Corvus Pharmaceuticals, Inc.: Current Employment. Miller:Corvus Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Angel Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees.